BioSpace News Archive

Anna Biosciences today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions announced today that it has entered into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis (ENXTPA: ALVTX), a pioneer in digital therapeutics.

jCyte, Inc. announced the further expansion of the company’s executive management team with the appointment of Adam Walsh, M.D. as Chief Financial Officer.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine, including the ability to purchase other COVID-19 vaccine candidates from Moderna’s pipeline.

BioSig Technologies, Inc., a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the data acquired by the PURE EP System would be featured in two presentations during the annual Heart Rhythm 2021 convention.

Phio Pharmaceuticals Corp. today announced that it has rescheduled the Company’s fireside chat being hosted by H.C. Wainwright for July 12th.

Breckenridge Pharmaceutical, Inc. announces that it has signed a multi-product agreement with Aggrega Pharma, LLC. under which Aggrega will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.

Gravity Diagnostics has promoted Karen Hargett to Vice President of Human Resources

Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the successful completion of a new round of financing totaling tens of millions of dollars.

Garwood Medical Devices, LLC, an emerging Buffalo-based company developing groundbreaking BioPrax™ technology to eliminate antibiotic-resistant bacterial biofilm infections associated with implants, has signed a memorandum of understanding with Integrum AB (Nasdaq First North Growth Market: INTEG B), a worldwide leader in helping individuals with amputations improve their quality of life through Integrum’s OPRA™ Implant System.